

Figure S1 Forest plot of risk ratios comparing pCR of patients treated with shorter-term versus long-term trastuzumab (except Z1041 trial).




Figure S2 Forest plot for pCR of subgroup by anti-HER2 therapy.

	short		long		Risk Ratio		Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% CI
11.1.1 HR-							
neoCARH	16	33	22	34	21.3%	0.75 [0.49, 1.15]	
TBCRC023	2	10	4	22	3.1%	1.10 [0.24, 5.05]	
Z1041	38	54	45	58	33.9%	0.91 [0.73, 1.13]	
Subtotal (95% CI)		97		114	58.3%	0.87 [0.72, 1.06]	•
Total events	56		71				
Heterogeneity: Tau² = 0.00; Chi² = 0.70, df = 2 (P = 0.70); l² = 0%							
Test for overall effect: $Z = 1.34$ (P = 0.18)							
11.1.2 HR+							
neoCARH	9	34	16	34	12.5%	0.56 [0.29, 1.09]	
TBCRC023	2	23	13	39	3.7%	0.26 [0.06, 1.05]	-
Z1041	40	84	32	84	25.5%	1.25 [0.88, 1.78]	
Subtotal (95% CI)		141		157	41.7%	0.68 [0.30, 1.56]	
Total events	51		61				
Heterogeneity: Tau² = 0.38; Chi² = 8.32, df = 2 (P = 0.02); i² = 76%							
Test for overall effect: Z = 0.90 (P = 0.37)							
Total (95% CI)		238		271	100.0%	0.86 [0.65, 1.13]	—
Total events	107		132				
Heterogeneity: Tau ² = 0.05; Chi ² = 9.17, df = 5 (P = 0.10); i ² = 45% 0.1 0.2 0.5 1 2 5 10							
Test for overall effect: $Z = 1.09$ (P = 0.27)							Favours [experimental] Favours [control]
Test for subaroup differences: Chi ² = 0.33, df = 1 (P = 0.57), i ² = 0%							

Figure S3 Forest plot for pCR of subgroup by estrogen receptor status.